At Abcodia we strive to change the way serum biomarkers are used to detect chronic diseases. We specialize in investigating the dynamic change of biomarkers over a disease lifecycle. Through longitudinal profiling of biomarkers, we can use the healthy baseline of an individual to improve the performance of diagnostic tests. Identifying change from baseline, rather than assessing static biomarker levels, can reduce false positives and false negatives and detect the disease earlier.
Abcodia’s unique longitudinal biobank of serum, derived from a population of 202,000 initially cancer-free postmenopausal women, allows studies profile how biomarkers change as diseases develop. This resource removes the significant hurdles of time and cost of a de novo sample collection that would normally be required to perform such studies.